Corpus overview


Overview

MeSH Disease

Human Phenotype

Dyspnea (23)

Fever (21)

Cough (20)

Fatigue (11)

Hypertension (10)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 23
    records per page




    Lower Rate of COVID-19 in Lupus Patients Receiving Immunosuppressive Drug Regimens

    Authors: Mohammadrafi Damirchi; Gholamreza Roshandel; Mehrdad Aghaie; Sima Sedighi; Mohammadjavad Hassani; Nafiseh Abdolahi

    doi:10.21203/rs.3.rs-78704/v1 Date: 2020-09-16 Source: ResearchSquare

    Introduction Recently, due to the COVID-19 pandemic much concern has been raised about chronic diseases, which could possibly make patients more susceptible, and vulnerable to COVID-19. One of them, is Systemic Lupus Erythematosus HP Systemic Lupus Erythematosus MESHD( SLE MESHD). Objective This study has tried to find the prevalence SERO of COVID-19 in SLE MESHD patients in Golestan province of Iran, and to characterize the clinical course of COVID-19 in these patients. This study has also sought to find possible correlation between the incidence of COVID-19, its clinical manifestations and the medication taken by SLE MESHD patients. Methods We investigated patients who had been enrolled in our rheumatologic diseases MESHD registry system. Patients responded to a questionnaire which contained questions about their primary disease, comorbidities, medications, development of new symptoms, and medical services which they received, pertinent to COVID-19, during the period of COVID-19 outbreak. The data were analyzed using SPSS 16 software. Results This investigation found 25 (7%) COVID-19 positive patients out of the 355 responders. 8 (40%) of them were hospitalized, out of which 2 (8%) required intensive care and later expired. COVID-19 incidence was significantly lower in the immunosuppressed group (2.2% vs 10% P-value 0.005). We didn’t find a significant correlation between hydroxychloroquine consumption, and the incidence of COVID-19 in SLE MESHD patients. Fever HP Fever MESHD, fatigue HP fatigue MESHD, dyspnea HP dyspnea MESHD, and dry cough MESHD cough HP were the most common clinical symptoms.Conclusion Our research has shown that COVID-19 prevalence SERO was lower in immunosuppressed patients. However, broader studies should be conducted to clarify the role of immunosuppression in the development of COVID-19. More research is required.

    The major predictors of testing positive for COVID-19 among symptomatic hospitalized patients

    Authors: Samson Barasa; David Tarazona; Faviola Valdivia Guerrero; Nancy Rojas Serrano; Dennis Carhuaricra; Lenin Maturrano Hernandez; Ronnie Gavilan Chavez

    doi:10.1101/2020.09.11.20192963 Date: 2020-09-13 Source: medRxiv

    The major predictors of testing positive for COVID-19 among symptomatic hospitalized patients Samson Barasa,1 Amy Ballard,1 Josephine Kiage-Mokaya, 1 Michael Friedlander,1 Geraldine Luna,2 1PeaceHealth Sacred Heart 2University of Illinois at Chicago Introduction: Increasing corona virus disease MESHD 2019 (COVID-19) pre-test probability can minimize testing patients who are less likely to have COVID-19 and therefore reducing personal protective equipment and COVID-19 testing kit use. The aim of this study was to identify patients who were likely to test positive for COVID-19 among symptomatic patients suspected of having COVID-19 during hospitalization by comparing COVID-19 positive and negative patients. Method: We conducted a retrospective chart review of patients who were [≥]18 years old and underwent COVID-19 Polymerase chain reaction test because they presented with symptoms thought to be due to COVID-19. A Poisson regression analysis was conducted after clinical presentation, demographic, medical co-morbidities, laboratory and chest image data was retrieved from the medical records. Results: Charts of 277 and 18 COVID-19 negative and positive patients respectively were analyzed. Dyspnea HP Dyspnea MESHD (61%) was the most common symptom among COVID-19 negative patients, while 72% and 61% COVID-19 positive patients had cough HP cough MESHD and fever HP fever MESHD respectively. COVID-19 positive patients were more likely to present initially with cough HP [1.082 (1.022 - 1.145)], fever HP fever MESHD [1.066 (1.014 - 1.121)] and be 50 to 69 years old [1.094 (1.021 - 1.172)]. Dyspnea HP Dyspnea MESHD, weakness MESHD, lymphopenia HP lymphopenia MESHD and bilateral chest image abnormality were not associated with COVID-19 positivity. COVID-19 positive patients were less likely to have non-COVID-19 respiratory viral illness [1.068 (1.019 - 1.119)], human immunodeficiency HP immunodeficiency MESHD virus [0.849 (0.765 - 0.943)] and heart failure MESHD history [0.093 (0.891 - 0.978)]. Other chronic medical problems ( hypertension HP hypertension MESHD, diabetes mellitus HP diabetes mellitus MESHD, chronic obstructive pulmonary disease HP chronic obstructive pulmonary disease MESHD and coronary artery disease MESHD) were not associated with testing positive for COVID-19. Conclusion: Cough HP, fever HP fever MESHD and being 50 to 69 years old are better predictors of symptomatic COVID-19 positivity during hospitalization. Despite published studies reporting a high prevalence SERO of lymphopenia HP lymphopenia MESHD among COVID-19 positive patients, lymphopenia HP lymphopenia MESHD is not associated with the risk of testing positive for COVID-19. Key Words: COVID-19, Predictors, Symptomatic, Hospitalized

    Prevalence SERO and correlation of symptoms and comorbidities in COVID-19 patients: A systematic review and meta-analysis

    Authors: Mohammad Meshbahur Rahman; Badhan Bhattacharjee; Zaki Farhana; Mohammad Hamiduzzaman; Muhammad Abdul Bake Chowdhury; Mohammad Sorowar Hossain; Mahbubul H Siddiqee; Md. Ziaul Islam; Enayetur Raheem; Md. Jamal Uddin

    doi:10.1101/2020.08.19.20177980 Date: 2020-08-22 Source: medRxiv

    Background: The COVID-19 affected millions of people, and the patients present a constellation of symptoms and comorbidities. We aimed to chronicle the prevalence SERO and correlations of symptoms and comorbidities, and associated covariates among the patients. Methods: We performed a systematic review and meta-analysis [PROSPERO registration: CRD42020182677]. Databases [PubMed, SCOPUS, EMBASE, WHO, Semantic Scholar, and COVID-19 Primer] were searched for clinical studies published in English from January 1 to April 20, 2020. The pooled prevalence SERO of symptoms and comorbidities were identified using the random effect model, and sub-groups analysis of patients age TRANS and locations were investigated. A multivariable factor analysis was also performed to show the correlation among symptoms, comorbidities and age TRANS of the COVID-19 patients. Findings: Twenty-nine articles [China (24); Outside of China (5)], with 4,884 COVID-19 patients were included in this systematic review. The meta-analysis investigated 33 symptoms, where fever HP fever MESHD [84%], cough HP cough MESHD/dry cough HP [61%], and fatigue HP fatigue MESHD/weakness [42%] were found frequent. Out of 43 comorbidities investigated, acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD) [61%] was a common condition, followed by hypertension HP hypertension MESHD [23%] and diabetes MESHD [12%]. According to the patients age TRANS, the prevalence SERO of symptoms like fatigue HP fatigue MESHD/weakness, dyspnea HP dyspnea MESHD/shortness of breath, and anorexia HP anorexia MESHD were highly prevalent in older adults TRANS [[≥]50 years] than younger adults TRANS [<50 years]. Diabetes MESHD, hypertension HP hypertension MESHD, coronary heart disease MESHD, and COPD MESHD/ lung disease MESHD were more prevalent comorbidities in older adults TRANS than younger adults TRANS. The patients from outside of China had significantly higher prevalence SERO [p<0.005] of diarrhea HP diarrhea MESHD, fatigue HP fatigue MESHD, nausea HP nausea MESHD, sore throat, and dyspnea HP dyspnea MESHD, and the prevalent comorbidities in that region were diabetes MESHD, hypertension HP hypertension MESHD, coronary heart disease MESHD, and ARDS MESHD. The multivariable factor analysis showed positive association between a group of symptoms and comorbidities, and with the patients age TRANS. Interpretation: Epitomizing the correlation of symptoms of COVID-19 with comorbidities and patients age TRANS would help clinicians effectively manage the patients.

    Asthma HP and COVID-19 - A systematic review

    Authors: Natália F. Mendes; Carlos P. Jara; Eli Mansour; Eliana P. Araújo; Licio Velloso

    doi:10.21203/rs.3.rs-53998/v1 Date: 2020-08-05 Source: ResearchSquare

    BackgroundSevere coronavirus disease-19 (COVID-19) presents with progressive dyspnea HP dyspnea MESHD, which results from acute lung inflammatory edema MESHD edema HP leading to hypoxia MESHD. As with other infectious diseases MESHD that affect the respiratory tract, asthma HP has been cited as a potential risk factor for severe COVID-19. However, conflicting results have been published over the last few months and the putative association between these two diseases is still unproven.MethodsHere, we systematically reviewed all reports on COVID-19 published since its emergence in December 2019 to May 18, 2020, looking into the description of asthma HP asthma MESHD as a premorbid condition, which could indicate its potential involvement in disease progression.ResultsWe found 169 articles describing the clinical characteristics of 36,072 patients diagnosed with COVID-19. Asthma HP was reported as a premorbid condition in only 655 patients accounting for 1.8% of all patients.ConclusionsAs the global prevalence SERO of asthma HP is 4.4%, we conclude that either asthma HP asthma MESHD is not a premorbid condition that contributes to the development of COVID-19 or clinicians and researchers are not accurately describing the premorbidities in COVID-19 patients.

    Impact of Corticosteroids and Immunosuppressive Therapies on Symptomatic SARS-CoV-2 Infection MESHD in a Large Cohort of Patients with Chronic Inflammatory Arthritis MESHD Arthritis HP

    Authors: Ennio Giulio Favalli; Serena Bugatti; Catherine Klersy; Martina Biggioggero; Silvia Rossi; Orazio De Lucia; Francesca Bobbio-Pallavicini; Antonella Murgo; Silvia Balduzzi; Roberto Caporali; Carlomaurizio Montecucco

    doi:10.21203/rs.3.rs-51667/v1 Date: 2020-07-31 Source: ResearchSquare

    Background: Prevalence SERO and outcomes of Coronavirus Disease MESHD ( COVID MESHD)-19 in relation to immunomodulatory medications are still unknown. The aim of the study is to investigate the impact of glucocorticoids and immunosuppressive agents on COVID MESHD-19 in a large cohort of patients with chronic immune-mediated inflammatory arthritis MESHD arthritis HP.Methods: The study was conducted in the arthritis HP arthritis MESHD outpatient clinic at two large Academic Hospitals in the COVID MESHD-19 most endemic area of Northern Italy (Lombardy). We circulated a cross-sectional survey exploring the prevalence SERO of Severe Acute Respiratory Syndrome-Coronavirus-2 MESHD nasopharyngeal swab positivity and the occurrence of acute respiratory illness MESHD ( fever HP and/or cough HP and/or dyspnea HP dyspnea MESHD), administered face-to-face or by phone to consecutive patients from 25th February to 20th April 2020. COVID MESHD-19 cases were defined as confirmed or highly suspicious according to the World Health Organization criteria. The impact of medications on COVID MESHD-19 incidence was evaluated. Results: The study population included 2050 adults TRANS with chronic inflammatory arthritis MESHD arthritis HP receiving glucocorticoids, conventional-synthetic (cs), or targeted-synthetic/biological (ts/b) disease-modifying drugs (DMARDs). Laboratory-confirmed COVID MESHD-19 and highly suspicious infection MESHD were recorded in 1.1% and 1.4% of the population, respectively. Treatment with glucocorticoids was independently associated with increased risk of COVID MESHD-19 (adjusted OR [95% CI] ranging from 1.23 [1.04-1.44] to 3.20 [1.97-5.18] depending on the definition used). Conversely, patients treated with ts/bDMARDs were at reduced risk (adjusted OR ranging from 0.46 [0.18-1.21] to 0.47 [0.46-0.48]). No independent effects of csDMARDs were observed.Conclusions: During the COVID MESHD-19 outbreak, treatment with immunomodulatory medications appears safe. Conversely, glucocorticoids, even at low-dose, may confer increased risk of infection TRANS risk of infection TRANS.Trial registration:  retrospectively registered

    Determinants of SARS-CoV-2 infection MESHD in Italian healthcare workers: a multicenter study

    Authors: Paolo Boffetta; Francesco Violante; Paolo Durando; Giuseppe De Palma; Enrico Pira; Luigi Vimercati; Alfonso Cristaudo; Giancarlo Icardi; Emma Sala; Maurizio Coggiola; Silvio Tafuri; Vittorio Gattini; Pietro Apostoli; Giovanna Spatari; - Working Group on SARS-CoV-2 infection in Italian healthcare workers

    doi:10.1101/2020.07.29.20158717 Date: 2020-07-30 Source: medRxiv

    Background. Healthcare workers (HCW) are at increased risk of being infected with SARS-CoV-2, yet limited information is available on risk factors of infection MESHD. Methods. We pooled data on occupational surveillance of 10,654 HCW who were tested for SARS-CoV-2 infection MESHD in six Italian centers. Information was available on demographics, job title, department of employment, source of exposure, use of personal protective equipment (PPE), and COVID-19-related symptoms. We fitted multivariable logistic regression models to calculate odds ratios (OR) and 95% confidence intervals (CI). Findings. The prevalence SERO of infection varied across centers and ranged from 3.0% to 22.0%, being strongly correlated with that of the respective areas. Women were at lower risk of infection TRANS risk of infection TRANS infection MESHD compared to men. Fever HP Fever MESHD, cough HP cough MESHD, dyspnea HP dyspnea MESHD and malaise were the symptoms most strongly associated with infection MESHD, together with anosmia HP anosmia MESHD and ageusia MESHD. No differences in the risk of infection TRANS risk of infection TRANS infection MESHD were detected between job titles, or working in a COVID-19 designated department. Reported contact with a patient inside or outside the workplace was a risk factor. Use of a mask was strongly protective against risk of infection TRANS risk of infection TRANS infection MESHD as was use of gloves. The use of a mask by the source of exposure (patient or colleague) had an independent effect in reducing infection risk TRANS infection risk TRANS.

    Clinical characteristics and Mortality risk factors among COVID-19 patients in Qom–Iran; The results of a Retrospective Cohort study

    Authors: Ahmad Hormati; SeyedYaser Foroghi Ghomi; masoudreza sohrabi; Ali Gholami; Saeede Jafari; Amir Jabbari; Reza AminNejad; Javad Khodadadi; Mansoureh shakeri; Alireza ShahHamzeh; Mahbobeh Afifian; Zohre Azad; Sajjad Ahmadpour; MohammadHadi Karbalai; MohammadReza Babaei; Parisa Karimzadeh; SeyedKamal Esshagh Hosseini

    doi:10.21203/rs.3.rs-42497/v1 Date: 2020-07-13 Source: ResearchSquare

    Background & AimCoronavirus 2019 (COVID-19) outbreak in the Middle East was initially reported in Qom-Iran. Clinical and epidemiologic and mortality risk factors details have not been already fully explained.MethodIn a retrospective study, the hospitalized adult TRANS patients with laboratory diagnosed COVID-19 between February 25 to March 20, 2020 were enrolled. A checklist including demographic, clinical, laboratorial, imaging, and treatment data was completed for each of the participant. The data were extracted from electronic medical records. In case of lack of information, a member of the research team contacted them via phone. All the dead patients and the first one hundred survived patients with these criteria were enrolled in the study. Outcome defined as death MESHD or discharge of patients.ResultsOf admitted patients, 200 patients who had been discharged or died were involved in this study. The majority of them were male TRANS (56%). The mean age TRANS of all patients was 62.63 ± 14.9. Co-morbidity was reported in 124 (62%) patients in which hypertension HP hypertension MESHD was the most common. The most frequent clinical presentations were dyspnea HP dyspnea MESHD in 169 (84.5%), cough HP cough MESHD in 150 (75%), and fatigue HP fatigue MESHD/weakness in 123 (61.5%) patients. The main complications were respiratory failure HP respiratory failure MESHD and acute respiratory distress syndrome MESHD respiratory distress HP syndrome with prevalence SERO of 143 (71.5%) and 105 (52.5%), accordingly. Multiple logistic models showed that decline of hemoglobin level (OR = 10.09), neutrophilia HP (OR = 3.48), high blood SERO urea nitrogen (OR = 4.29,), SpO2 ≤ 90% (OR = 3.38), and presence of patchy consolidation (OR = 6.81) were associated with poor outcome.ConclusionCOVID-19 disease has multiple aspects. CT scan findings, complete blood SERO count with differential, high blood SERO urea nitrogen and SpO2 are related to mortality. Hence needs to pay serious attention during admitting and surveillance, particularly among elderly TRANS patients and who with preexisting morbidities.

    The influence of comorbidity on the severity of COVID-19 disease: A systematic review and analysis

    Authors: Nazar Zaki; Elfadil Abdalla Mohamed; Sahar Ibrahim; Gulfaraz Khan

    doi:10.21203/rs.3.rs-37127/v2 Date: 2020-06-20 Source: ResearchSquare

    Background: A novel form of coronavirus disease MESHD (SARS-CoV-2) has spread rapidly across the world. What risk factors influence the severity of the disease is of considerable importance.Aim: This research offers a systematic review and meta-analysis of the correlation between common clinical conditions and comorbidities and the severity of COVID-19.Methodology: Two independent researchers searched Europe PMC, Google Scholar, and PubMed databases for articles related to influence comorbidities have on the progress of the disease. A search engine was also created to screen a further 59,000 articles in COVID-19 Open Research Dataset (CORD-19). Random-effects modeling was used to pool 95% confidence intervals (CIs) and odds ratios (ORs). The significance of all comorbidities and clinical conditions to the severity of the disease was evaluated by employing machine-learning techniques. Publication bias was assessed by using funnel-plots and Egger’s test. Heterogeneity was tested using I2.Results: The meta-analysis incorporated 12 studies spanning 4,101 confirmed COVID-19 patients who were admitted to Chinese hospitals. The prevalence SERO of the most commonly associated co-morbidities and their corresponding odds ratio for disease severity were as follows: coronary heart disease MESHD (OR 2.97 [CI: 1.99-4.45], p < 0.0001), cancer MESHD (OR 2.65 [CI: 1.12-6.29], p < 0.03), cardiovascular disease MESHD (OR 2.89 [CI: 1.90-4.40], p < 0.0001), COPD MESHD (OR 3.24 [CI: 1.66-6.32], p = 0.0), and kidney disease MESHD (OR 2.2.4 [CI: 1.01-4.99], p = 0.05) with low or moderate level of heterogeneity. The most frequently exhibited clinical symptoms were fever HP fever MESHD (OR 1.37 [CI: 1.01-1.86], p = 0.04), myalgia HP myalgia MESHD/ fatigue HP fatigue MESHD (OR 1.31 [CI: 1.11-1.55], p = 0.0018), and dyspnea HP dyspnea MESHD (OR 3.61, [CI: 2.57-5.06], p = <0.0001). No significant associations between disease severity and liver disease MESHD, smoking habits, and other clinical conditions, such as a cough HP, respiratory/ARDS, diarrhea HP diarrhea MESHD or chest tightness HP chest tightness MESHD/ pain HP pain MESHD were found. The meta-analysis also revealed that the incubation period TRANS was positively associated with disease severity. Conclusion: Existing comorbidities, including COPD, cardiovascular disease MESHD, and coronary heart disease MESHD, increase the severity of COVID-19. Some studies found a statistically significant association between comorbidities such as diabetes MESHD and hypertension HP hypertension MESHD and disease severity. However, these studies may be biased due to substantial heterogeneity. 

    The influence of comorbidity on the severity of COVID-19 disease: A scoping review and meta-analysis

    Authors: Nazar Zaki; Elfadil Abdalla Mohamed; Sahar Ibrahim; Gulfaraz Khan

    doi:10.21203/rs.3.rs-37127/v3 Date: 2020-06-20 Source: ResearchSquare

    Background: A novel form of coronavirus disease MESHD (SARS-CoV-2) has spread rapidly across the world. What risk factors influence the severity of the disease is of considerable importance. Objectives: This research offers a systematic review and meta-analysis of the correlation between common clinical conditions and comorbidities and the severity of COVID-19. Methodology: Two independent researchers searched Europe PMC, Google Scholar, and PubMed databases for articles related to influence comorbidities have on the progress of the disease. A search engine was also created to screen a further 59,000 articles in COVID-19 Open Research Dataset (CORD-19). Random-effects modeling was used to pool 95% confidence intervals (CIs) and odds ratios (ORs). The significance of all comorbidities and clinical conditions to the severity of the disease was evaluated by employing machine-learning techniques. Publication bias was assessed by using funnel-plots and Egger’s-test. Heterogeneity was tested using I2. Results: The meta-analysis incorporated 12 studies spanning 4,101 confirmed COVID-19 patients who were admitted to Chinese hospitals. The prevalence SERO of the most commonly associated co-morbidities and their corresponding odds ratio for disease severity were as follows: coronary heart disease (OR 2.97 [CI: 1.99-4.45], p < 0.0001), cancer (OR 2.65 [CI: 1.12-6.29], p < 0.03), cardiovascular disease (OR 2.89 [CI: 1.90-4.40], p < 0.0001), COPD (OR 3.24 [CI: 1.66-6.32], p = 0.0), and kidney disease (OR 2.2.4 [CI: 1.01-4.99], p = 0.05) with low or moderate level of heterogeneity. The most frequently exhibited clinical symptoms recorded during the course of admission were fever HP (OR 1.37 [CI: 1.01-1.86], p = 0.04), myalgia HP/ fatigue HP (OR 1.31 [CI: 1.11-1.55], p = 0.0018), and dyspnea HP (OR 3.61, [CI: 2.57-5.06], p = <0.0001). No significant associations between disease severity and liver disease, smoking habits, and other clinical conditions, such as a cough HP, respiratory/ARDS, diarrhea HP or chest tightness HP/ pain HP were found. The meta-analysis also revealed that the incubation period TRANS was positively associated with disease severity. Conclusion: Existing comorbidities, including COPD, cardiovascular disease, and coronary heart disease, increase the severity of COVID-19. Some studies found a statistically significant association between comorbidities such as diabetes and hypertension HP and disease severity. However, these studies may be biased due to substantial heterogeneity.

    SEROPREVALENCE SERO AND CLINICAL SPECTRUM OF SARS-CoV-2 INFECTION IN MESHD THE FIRST VERSUS THIRD TRIMESTER OF PREGNANCY

    Authors: Francesca Crovetto; Fatima Crispi; Elisa Llurba; Francesc Figueras; Maria Dolores Gomez-Roig; Eduard Gratacos

    doi:10.1101/2020.06.17.20134098 Date: 2020-06-19 Source: medRxiv

    Introduction: Case registries of pregnant women diagnosed with coronavirus disease MESHD (COVID-19) by polymerase chain reaction (PCR) have reported that the majority experienced mild infection MESHD, but up to 9% may require critical care. Most COVID-19 cases published were in the third trimester of pregnancy, which could reflect reporting bias, higher risk of infection TRANS risk of infection TRANS infection MESHD or increased disease severity in late pregnancy. Seroprevalence SERO studies may allow reliable estimates of the susceptibility to infection MESHD and clinical spectrum since they include asymptomatic TRANS and mild infections not tested for PCR. We evaluated the seroprevalence SERO and clinical presentation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD in pregnant women in the first and third trimester. Methods: The study was approved by the Institutional Review Board at each institution and informed consent was obtained. We recruited 874 consecutive pregnancies attending for first trimester screening (10-16 weeks of gestation, n=372) or delivery (n=502) from April 14 to May 5. All women were interviewed with a structured questionnaire for COVID-19 symptoms two months prior to sampling. SARS-CoV-2 IgG and IgM/IgA antibodies were tested SERO (COVID-19 VIRCLIA Monotest, Vircell Microbiologist, Spain; reported sensitivity SERO 70% IgG and 89% IgM/IgA, and specificity 89% and 99% respectively). Indeterminate results were re-tested (VITROS Immunodiagnostic Products Anti-SARS-CoV2 Total Tests, Ortho Clinical Diagnostics, USA; 100% sensitivity SERO and specificity) and re-classified as positive or negative. Women with COVID-19 were diagnosed and managed according to standard protocols and guidelines3,4. Statistical differences were tested using the {chi}2 test or Student t-test as appropriate (p<0.05). Results: A total of 125 of 874 women (14.3%) were positive for either IgG or IgM/IgA SARS-CoV-2 antibodies SERO, 54/372 (14.5%) in the first and 71/502 (14.1%) in the third trimester. A total of 75/125 (60%) reported no symptoms of COVID-19 in the past 2 months, whereas 44 (35.2%) reported one or more symptoms, of which 31 (24.8%) had at least 3 symptoms or anosmia HP anosmia MESHD and 8 (6.4%) dyspnea HP dyspnea MESHD. Overall, 7 women (5.6%) were admitted for persistent fever HP fever MESHD despite paracetamol and dyspnea HP dyspnea MESHD, of which 3 had signs of pneumonia HP pneumonia MESHD on chest radiography. All 3 had criteria for severity (bilateral chest condensation, respiratory rate>30 and leukopenia HP leukopenia MESHD) and required oxygen support but not critical care or mechanical ventilation, and they were all discharged well. The rates of symptomatic infection MESHD, hospital admission or dyspnea HP dyspnea MESHD were significantly higher in third trimester women (Table and Figure). Discussion: The 14.3% seroprevalence SERO of SARS-COV-2 in pregnant women in this study was substantially larger than the contemporary rates of PCR positive cases (0.78%) reported for women 20-40y in Barcelona. The data confirm that COVID-19 is asymptomatic TRANS in the majority of pregnant women6 and illustrate the value of seroprevalence SERO studies to capture the high proportion of asymptomatic TRANS or mild infections MESHD. In this study, none of the 125 pregnant women with SARS-CoV-2 infection MESHD required critical care as compared to 9% reported in cases diagnosed with PCR. However, the proportion of infections MESHD with symptoms or dyspnea HP dyspnea MESHD was remarkably higher in the third trimester, and these results are in line with COVID-19 registries, reporting that 81% of hospitalized women were in late pregnancy or peripartum. These results provide reassuring information that, even in settings with a high prevalence SERO, SARS-CoV-2 infection MESHD in pregnancy mostly presents with asymptomatic TRANS or mild clinical forms. The susceptibility to infection seemed to be the same in the first and the third trimesters of gestation. The data further suggest that, as with other respiratory viruses, COVID-19 could be more severe and require increased surveillance in late pregnancy. These findings should be confirmed and extended with larger consecutive prevalence SERO studies in pregnancy.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.